Cancer Care Ontario | Cancer Care Ontario

niraparib - For the maintenance treatment of newly diagnosed or recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

niraparib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Mar 2025

Guidelines and Advice

Best Practice Guidance for Patient-Specific Quality Assurance for IMRT and VMAT Plan Delivery Verification

Status: Current

Oct 2019

Drug

niraparib

Other Name(s): Zejula

Quick Link(s):

Drug Monograph, Patient Info Sheet

Mar 2025

Guidelines and Advice

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Status: Current

Mar 2025

ALEM

GEMC

CRBPDOXO

Somatic Cancer Panel Reporting in Ontario

Oncology Caregiver Support Framework

Indications for Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines: January to June 2019

EVERLENV

NIRP

Best Practice Guidance for Patient-Specific Quality Assurance for IMRT and VMAT Plan Delivery Verification

niraparib

T-Cell Engaging Antibodies: Management of Cytokine Release Syndrome (CRS) and Immune Effector-Associated Neurotoxicity Syndrome (ICANS)

Pages